Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study

被引：2

作者：

Furubayashi, Nobuki ^{[1
]}

Morokuma, Futoshi ^{[2
]}

Tomoda, Toshihisa ^{[3
]}

Hori, Yoshifumi ^{[4
]}

Negishi, Takahito ^{[1
]}

Miura, Akihiro ^{[1
]}

Komori, Hiroki ^{[1
]}

Kuroiwa, Kentaro ^{[4
]}

Nakamura, Motonobu ^{[1
]}

机构：

[1] Natl Hosp Org Kyushu Canc Ctr, Dept Urol, Fukuoka, Japan

[2] Saga Ken Med Ctr Koseikan, Dept Urol, Saga, Japan

[3] Oita Prefectural Hosp, Dept Urol, Oita, Japan

[4] Miyazaki Prefectural Miyazaki Hosp, Dept Urol, Miyazaki, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 03期

关键词：

chemotherapy pembrolizumab; real -world clinical practice; Advanced urothelial carcinoma; platinum-based; IMMUNE CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; GEMCITABINE; CARBOPLATIN; CISPLATIN; CANCER; TUMORS; CELLS;

D O I：

10.21873/anticanres.15631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The optimal timing of switching from platinum-based chemotherapy to pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear. Patients and Methods: Thirty-four patients who received pembrolizumab as second-line treatment after firstline platinum-based chemotherapy were retrospectively evaluated. Results: According to overall survival (OS) from pembrolizumab, there was a significant difference between <= 4 and 0.001), but not between <= 6 and 6 cycles (18.6 and 27.3 months, p=0.276). Conclusion: The optimal timing of switching from platinum-base chemotherapy to pembrolizumab in advanced UC is around six cycles.

引用

页码：1571 / 1577

页数：7

共 50 条

[31] Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy
Nishikawa, A.
Hashimoto, H.
Takeda, M.
Kontani, K.
Miyatake, T.
Mimura, M.
Nagamatsu, M.
Yokoi, T.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2016, 37 (04) : 451 - 454
[32] Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study
Wang, Yang
Zhang, Xuanye
Tian, Dan
Han, Sen
Zhang, Jie
Nie, Jun
Dai, Ling
Hu, Weiheng
Chen, Xiaoling
Ma, Xiangjuan
Tian, Guangming
Wu, Di
Zhang, Ziran
Long, Jieran
Fang, Jian
CANCER MEDICINE, 2023, 12 (03): : 2303 - 2311
[33] A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study
Inoue, Takamitsu
Miyazaki, Jun
Ichioka, Daishi
Narita, Shintaro
Kageyama, Susumu
Sugimoto, Mikio
Mitsuzuka, Koji
Shiraishi, Yusuke
Kinoshita, Hidefumi
Wakeda, Hironobu
Nomoto, Takeshi
Kikuchi, Eiji
Matsui, Yoshiyuki
Fujie, Keiko
Habuchi, Tomonori
Nishiyama, Hiroyuki
BMC CANCER, 2018, 18
[34] Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
Qu, Yuan-Yuan
Sun, Zhongquan
Han, Weiqing
Zou, Qing
Xing, Nianzeng
Luo, Hong
Zhang, Xuepei
He, Chaohong
Bian, Xiao-Jie
Cai, Jinling
Chen, Chunxia
Wang, Quanren
Ye, Ding-Wei
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (05)
[35] Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients
Ito, Katsuhiro
Kita, Yuki
Kobayashi, Takashi
INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 696 - 703
[36] Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
Kutuk, Tugce
Appel, Haley
Avendano, Maria Carolina
Albrecht, Federico
Kaywin, Paul
Ramos, Suyen
Suarez-Murias, Melanie E.
Mehta, Minesh P.
Kotecha, Rupesh
CANCERS, 2022, 14 (08)
[37] Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab
Kato, Minoru
Kobayashi, Takashi
Matsui, Yoshiyuki
Ito, Katsuhiro
Hikami, Kensuke
Yamada, Takeshi
Ogawa, Kosuke
Nakamura, Kenji
Sassa, Naoto
Yokomizo, Akira
Abe, Takashige
Tsuchihashi, Kazunari
Tatarano, Shuichi
Inokuchi, Junichi
Tomida, Ryotaro
Fujiwara, Maki
Takahashi, Atsushi
Matsumoto, Kazumasa
Shimizu, Kosuke
Araki, Hiromasa
Kurahashi, Ryoma
Ozaki, Yu
Tashiro, Yu
Uegaki, Masayuki
Kojima, Takahiro
Uchida, Junji
Ogawa, Osamu
Nishiyama, Hiroyuki
Kitamura, Hiroshi
INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (12) : 1261 - 1267
[38] Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
Yang, Zhenyun
Wu, Weijie
Hu, Zhiwen
Fu, Yizhen
Hu, Zili
Pan, Yangxun
Wang, Juncheng
Chen, Jinbin
Zhou, Zhongguo
Zhang, Yaojun
Chen, Minshan
Hu, Dandan
FRONTIERS IN IMMUNOLOGY, 2024, 15
[39] Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study
Wu, Wen-Jie
Liu, Qian
An, Pu-Gen
Wang, Lin
Zhang, Jian-Yun
Chen, Yan
Zhang, Tong
Zhang, Jie
FRONTIERS IN IMMUNOLOGY, 2023, 14
[40] Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab
Sato, Ryo
Inamoto, Teruo
Matsushita, Yuto
Takemura, Ayana
Uchimoto, Taizo
Sano, Asuka
Tanaka, Hiroki
Ishikawa, Gaku
Watanabe, Kyohei
Watanabe, Hiromitsu
Tamura, Keita
Motoyama, Daisuke
Sugiyama, Takayuki
Otsuka, Atsushi
Harada, Ken-ichi
Azuma, Haruhito
Miyake, Hideaki
INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 730 - 736

← 1 2 3 4 5 →